Relapsing course – Talk Bio

FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

5 months ago talkbio0Tagged Acute leukemia, Approved, Chromosomal translocation, KMT2A gene, Menin Inhibitor, Relapsing course, Revuforj, Syndax, United States Food and Drug Administration, Unresponsive to Treatment

FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

7 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses

FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma

10 months ago talkbio0Tagged Antibodies, Bispecific, Approved, Engaged to be married, epcoritamab-bysp, EPKINLY, Lymphoma, Follicular, Relapsing course, Subcutaneous Treatment, T-Lymphocyte, United States Food and Drug Administration, Unresponsive to Treatment

EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment

Brukinsa Broadens Horizons: FDA Clears Follicular Lymphoma Combination Therapy

1 year ago talkbio0Tagged Accelerated, Approved, broadest label, Brukinsa, BTK Inhibitor, CHMP, Chronic lymphoma, Combined Modality Therapy, Lymphoma, Follicular, obinutuzumab, Oregon (geographic location), Overall response rate, Phase 2 Clinical Trials, Phase II ROSEWOOD trial, Recommendation, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Relapsing course, Rosewood, United States Food and Drug Administration

Brukinsa, Follicular lymphoma, FDA approval, BTK inhibitor, BTK inhibitor, Broadest label, Relapsed or refractory follicular lymphoma, ROSEWOOD Phase II study, CHMP positive opinion, Obinutuzumab combination therapy, Accelerated approval, Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma, Chronic lymphoma, CHMP recommendation, Phase II ROSEWOOD trial, Overall response rate (OR